Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:acquiredBy |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alternativeName |
gptkb:lisocabtagene_maraleucel
|
| gptkbp:antigen |
gptkb:CD19
|
| gptkbp:cellType |
autologous T cells
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Juno_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
JCAR017
|
| gptkbp:indication |
relapsed or refractory large B-cell lymphoma
|
| gptkbp:marketedAs |
gptkb:Breyanzi
|
| gptkbp:mechanismOfAction |
genetically engineered T cells to express chimeric antigen receptor
|
| gptkbp:regulates |
approved (as Breyanzi)
|
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome |
| gptkbp:usedFor |
B-cell malignancies
relapsed/refractory large B-cell lymphoma |
| gptkbp:bfsParent |
gptkb:Juno_Therapeutics
|
| gptkbp:bfsLayer |
5
|